BiomX Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
HLSQ$0.07-37.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets (unaudited)
CONDENSED CONSOLIDATED BALANCE SHEETS
| As of | ||
|---|---|---|
| September 30, 2025 | December 31, 2024 | |
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | 6,923 | 16,856 |
| Restricted cash | 985 | 958 |
| Other current assets | 954 | 2,706 |
| Total current assets | 8,862 | 20,520 |
| Non-current assets | ||
| Non-current restricted cash | 161 | 161 |
| Operating lease right-of-use assets | 2,091 | 5,457 |
| Property and equipment, net | 3,004 | 5,045 |
| In-process Research and development asset (“IPR&D”) | 12,050 | 12,050 |
| Total non-current assets | 17,306 | 22,713 |
| 26,168 | 43,233 | |
CONDENSED CONSOLIDATED BALANCE SHEETS
| As of | ||
|---|---|---|
| September 30, 2025 | December 31, 2024 | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities | ||
| Trade accounts payable | 1,508 | 1,882 |
| Current portion of lease liabilities | 1,296 | 1,130 |
| Other accounts payable | 2,422 | 5,255 |
| Total current liabilities | 5,226 | 8,267 |
| Non-current liabilities | ||
| Operating lease liabilities, net of current portion | 5,287 | 8,454 |
| Other liabilities | 34 | 77 |
| Warrants | 5,135 | 2,287 |
| Total non-current liabilities | 10,456 | 10,818 |
| Commitments and Contingencies (Note 6) | ||
| Stockholders’ equity | ||
| Preferred Stock, $0.0001 par value; Authorized – 1,000,000 shares as of September 30, 2025 and December 31, 2024. Issued and outstanding - 147,512 shares as of September 30, 2025 and 147,735 shares as of December 31, 2024. | 18,617 | 18,645 |
| Common Stock, $0.0001 par value; Authorized – 750,000,000 shares as of September 30, 2025 and December 31, 2024. Issued and outstanding- 26,800,980 shares as of September 30, 2025 and 18,176,661 shares as of December 31, 2024. | 7 | 6 |
| Additional paid in capital | 195,421 | 186,194 |
| Accumulated deficit | (203,559) | (180,697) |
| Total stockholders’ equity | 10,486 | 24,148 |
| 26,168 | 43,233 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.